SALVAGE TREATMENT OF PROGRESSIVE SEVERE CHRONIC GRAFT-VERSUS-HOST DISEASE BY IMMUNE ABLATION AND STEM CELL RESCUE IN 2 PEDIATRIC PATIENTS (EBMT 2023)
The IAT consisted of antithymocyte globulin Grafalon® (4 x 15 mg/kg), cyclophosphamide (2 x 60 mg/kg) and fludarabine (4 x 40 mg/m²)...Different therapeutic approaches with methylprednisolone pulses, infliximab, adalimumab, ofatumumab, ruxolitinib, pentostatin, sirolimus and extracorporeal photopheresis remained ineffective...Despite the application of methylprednisolone pulses, cyclosporine A, imatinib, ruxolitinib and extracorporeal photopheresis, the cGvHD progressed...Patient 2 has too few T cells for a meaningful Vβ-Spectratyping.CharacteristicsPatient 1Patient 2Age (years)1216SexfemalemaleDiagnosisB precursor ALLcommon ALLDonor of initial HSCTMSD (brother)MUDStem cell sourcebone marrowperipheral bloodConditioningTBI, VP-16TBI, VP-16, ATGGvHD prophylaxiscyclosporine Acyclosporine A, methotrexatecGvHD scoring before IATskin: 3, joints and fascia: 3, lungs: 2, eyes: 1skin: 3, joints and fascia: 3, lungs: 2, eyes: 1CD34+ content of stem cell rescue2.05 x 106/kg2.4 x 106/kgEngraftment after IATleucocytes > 109/l since day 9thrombocytes > 20 x 109/l since day 11leucocytes > 109/l since day 10thrombocytes > 20 x 109/l since day 11Response to IATcomplete responsepartial responsecGvHD scoring after IATskin: 0; joints and fascia: 0; lungs: 2 (residuum of cGvHD); eyes: 0skin: 2; joints and fascia: 2; lungs: 2; eyes: 0Virus reactivationCMVEBVImmunosuppression after IATdiscontinued on day 203low dose methylprednisolone (0.1 mg/kg/d)Last follow-upday 759 after stem cell rescueday 308 after stem cell rescue Two patients with life-threatening SR-cGvHD clearly benefitted from IAT with following re-transplantation of stem cells, while previous long-term immunosuppressive and biological treatment failed. Two patients with life-threatening SR-cGvHD clearly benefitted from IAT with following re-transplantation of stem cells, while previous long-term immunosuppressive and biological treatment failed. Until now, this concept has only been a therapeutic option in some refractory autoimmune diseases. More data is needed to re-evaluate the usage in SR-cGvHD.